News

In the study, Picoplatin, in combination with 5-fluorouracil and leucovorin (FOLPI regimen), was associated with a reduction in neurotoxicity compared to oxaliplatin given in combination with 5-fluorouracil and

The company claims that the Seal-Scan has been a successful inspection solution for many types of pouches and flexible packaging. Applications included in the system are: medical device

Pharming has submitted the MAA for Rhucin to the European Medicines Agency in September 2009, and the CHMP has issued the Day 120 List of Questions(LoQ) on 21

The international, Phase 3 trial compared sunitinib with placebo in patients with progressive, well-differentiated, malignant pancreatic neuroendocrine tumors. In the study the patients were randomised to either the

Anadys has also announced that all patients have commenced dosing in the second dose cohort, 400mg bid. With patient enrollment in this cohort completed, the company has accelerated

Michael French, president and CEO of MDRNA, said: “While our focus remains the development of RNAi-based therapeutics, we believe that the intranasal assets from our predecessor company, Nastech

The analysis indicates that patients with KRAS wild-type tumors bearing a BRAF mutation also benefit from Erbitux treatment; therefore, KRAS remains the only validated, clinically predictive marker of

The seal-inspection tool forms part of the PowerChek and PowerChek Plus x-ray inspection systems. These multi-tasking inspection tools are the technological defenders of brand values. They catch several

SOCMA has reported that, in the notice, EPA identified classes of facilities within the industry ‘for which the agency plans to develop, as necessary, a proposed regulation identifying